Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics Inc. is a clinical-stage biotechnology company developing bifunctional antibody therapies for solid tumors. Its lead candidate, ficerafusp alfa, combines an antibody that targets the epidermal growth factor receptor (EGFR) with a domain that traps transforming growth factor beta (TGF-beta), aiming to block tumor growth signals while reversing immune suppression within the tumor microenvironment.

The company's primary focus is head and neck squamous cell carcinoma, where ficerafusp alfa is being studied in combination with the immunotherapy pembrolizumab as a first-line treatment for recurrent or metastatic disease. It is also exploring the drug in other EGFR-driven cancers.

Bicara is headquartered in Boston, Massachusetts, and completed its initial public offering on Nasdaq in 2024.